Everything below concerns c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
=== Disease === Disease can arise if the host's protective immune mechanisms are compromised and the organism inflicts damage on the host. Microorganisms can cause tissue damage by releasing a variety of toxins or destructive enzymes. For example, Clostridium tetani releases a toxin that paralyzes muscles, and staphylococcus releases toxins that produce shock and sepsis. Not all infectious agents cause disease in all hosts. For example, less than 5% of individuals infected with polio develop disease. On the other hand, some infectious agents are highly virulent. The prion causing mad cow disease and Creutzfeldt–Jakob disease invariably kills all animals and people that are infected. Persistent infections occur because the body is unable to clear the organism after the initial infection. Persistent infections are characterized by the continual presence of the infectious organism, often as latent infection with occasional recurrent relapses of active infection. There are some viruses that can maintain a persistent infection by infecting different cells of the body. Some viruses once acquired never leave the body. A typical example is the herpes virus, which tends to hide in nerves and become reactivated when specific circumstances arise. Persistent infections cause millions of deaths globally each year. Chronic infections by parasites account for a high morbidity and mortality in many underdeveloped countries.
=== Film and television === AAA, la película: sin límite en el tiempo, a 2010 Mexican movie Anbanavan Asaradhavan Adangadhavan, a 2017 Indian Tamil-language movie Associated Argentine Artists (Spanish: Artistas Argentinos Asociados), an Argentine movie distribution company Spearhead from Space, a 1970 Doctor Who serial (production code "AAA")
Engines (includes all models from 1998 to 2003) 1.3 L B3-ME SOHC I4 1.5 L ZL-DE DOHC I4 1.5 L ZL-VE S-VT I4 1.6 L ZM-DE DOHC I4 1.8 L FP-DE DOHC I4 2.0 L FS, 130 hp (97 kW; 132 PS) / 135 lb⋅ft (183 N⋅m) 2.0 L FS-ZE (2001 Sport 20) 2.0 L RF Diesel
=== Wa === John E. Walker FRS (b. 1941). British biochemist at Cambridge University, known for studies of ATPases and ATP synthase. Nobel Prize for Chemistry (1997). Foreign associate Natl. Acad. Sci. USA. Michael Wakelam (1955–2020). British molecular biologist at Babraham Institute, Cambridge Selman Waksman (1888–1973). Ukrainian-American biochemist at Rutgers University, known for discovering streptomycin and other antibiotics. Nobel Prize in Physiology or Medicine (1952). Christopher T. Walsh (1944–2023). American biochemist at Harvard, known for work on enzymes and enzyme inhibition, and especially for his book Enzymatic Reaction Mechanisms. Member Natl. Acad. Sci. USA. James C. Wang, (b. 1938). Chinese-American biochemist at Harvard, known for the discovery of topoisomerases. Member Natl. Acad. Sci. USA Xiaodong Wang, (b. 1963), Chinese-American biochemist at the National Institute of Biological Sciences, Peking, known for his work with cytochrome c. Member Natl. Acad. Sci. USA. Otto Heinrich Warburg FRS (foreign member) (1883–1970). German biochemist at the Kaiser Wilhelm Institute for Cell Physiology (Berlin), who pioneered the study of respiration. Nobel Prize in Physiology or Medicine (1931). Arieh Warshel (b. 1940). Israeli-American biochemist and biophysicist at the University of Southern California, a pioneer in computational studies on functional properties of biological molecules. Nobel Prize in Chemistry (2013). Member Natl. Acad. Sci. USA. Foreign member of the Russian Academy of Sciences. James D. Watson FRS (foreign member) (1928–2025).
A material-dependent unit used in nuclear and particle physics and engineering to measure the thickness of shielding, for example around a nuclear reactor, particle accelerator, or radiation or particle detector. 1 mwe of a material is the thickness of that material that provides the equivalent shielding of one metre (≈39.4 in) of water. This unit is commonly used in underground science to express the extent to which the overburden (usually rock) shields an underground space or laboratory from cosmic rays. The actual thickness of overburden through which cosmic rays must traverse to reach the underground space varies as a function of direction due to the shape of the overburden, which may be a mountain, or a flat plain, or something more complex like a cliff side. To express the depth of an underground space in mwe (or kmwe for deep sites) as a single number, the convention is to use the depth beneath a flat overburden at sea level that gives the same overall cosmic ray muon flux in the underground location.
Sources: en.wikipedia.org
=== Experience of treatment === Patients involved in treatment sometimes felt that treatment focused on biological aspects of body weight and eating behaviour change rather than their perceptions or emotional state. Patients felt that a therapist's trust in them shown by being treated as a complete person with their own capacities was significant. Some patients defined recovery from AN in terms of reclaiming a lost identity. Additionally, access to timely treatment can be hindered by systemic challenges within the medical system. Some individuals have reported experiencing delays in treatment, particularly when transitioning from adolescence to adulthood. Healthcare workers involved in the treatment of anorexia reported frustration and anger to setbacks in treatment and noncompliance and were afraid of patients dying. Some healthcare workers felt that they did not understand the treatment and that medical doctors were making decisions. They may feel powerless to improve a patient's situation and deskilled as a result. Healthcare workers involved in monitoring patients consumption of food felt watched themselves. Healthcare workers often feel a degree of moral dissonance of not being in control of outcomes which they may protect against by focusing on individual tasks, avoiding identifying with patients (for example by making their eating behavior very different and not sharing personal information with patients), and blaming patients for their distress. Healthcare workers would inflexibly follow process to avoid responsibility.
Larson received media attention for scolding members of Congress for shutting down the government on September 30, 2013. Larson was among the 46 Democrats who voted against final passage of the Fiscal Responsibility Act of 2023 in the House.
Another aspect of QD toxicity is that there are, in vivo, size-dependent intracellular pathways that concentrate these particles in cellular organelles that are inaccessible by metal ions, which may result in unique patterns of cytotoxicity compared to their constituent metal ions. The reports of QD localization in the cell nucleus present additional modes of toxicity because they may induce DNA mutation, which in turn will propagate through future generation of cells, causing diseases. Although concentration of QDs in certain organelles have been reported in in vivo studies using animal models, no alterations in animal behavior, weight, hematological markers, or organ damage has been found through either histological or biochemical analysis. These findings have led scientists to believe that intracellular dose is the most important determining factor for QD toxicity. Therefore, factors determining the QD endocytosis that determine the effective intracellular concentration, such as QD size, shape, and surface chemistry determine their toxicity. Excretion of QDs through urine in animal models also have demonstrated via injecting radio-labeled ZnS-capped CdSe QDs where the ligand shell was labeled with 99mTc. Though multiple other studies have concluded retention of QDs in cellular levels, exocytosis of QDs is still poorly studied in the literature. While significant research efforts have broadened the understanding of toxicity of QDs, there are large discrepancies in the literature, and questions still remain to be answered.
Galanin-like peptide (GALP) is a neuropeptide present in humans and other mammals. It is a 60-amino acid polypeptide produced in the arcuate nucleus of the hypothalamus and the posterior pituitary gland. It is involved in the regulation of appetite and may also have other roles such as in inflammation, sex behavior, and stress. Findings additionally suggest that GALP could play a function in energy metabolism due to its ability to maintain continual activation of the sympathetic nervous system (SNS) via thermogenesis, which refers to the production of heat within living organisms. In addition, the administration of GALP directly into the brain leads to a reduction in the secretion of thyroid-stimulating hormone (TSH), which indicates the involvement of GALP in the neuroendocrine regulation of the hypothalamic-pituitary-thyroid (HPT) axis, and further adding to the evidence of the role of GALP in energy homeostasis.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.